MARKET

NVRO

NVRO

Nevro
NYSE

Real-time Quotes | Nasdaq Last Sale

93.96
-1.31
-1.38%
After Hours: 93.04 -0.92 -0.98% 16:11 04/03 EDT
OPEN
92.23
PREV CLOSE
95.27
HIGH
95.96
LOW
89.57
VOLUME
573.83K
TURNOVER
--
52 WEEK HIGH
148.05
52 WEEK LOW
54.00
MARKET CAP
2.99B
P/E (TTM)
-27.7832
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NVRO stock price target is 131.78 with a high estimate of 170.00 and a low estimate of 100.00.

EPS

NVRO News

More
  • Nevro Announces the Full Exercise of the Underwriter's Option to Purchase Additional Common Stock and the Underwriter's Over-allotment Option to Purchase Additional Convertible Senior Notes
  • PR Newswire · 21h ago
  • Morgan Stanley Maintains Overweight on Nevro, Lowers Price Target to $113
  • Benzinga · 1d ago
  • Nevro (NVRO) Looks Good: Stock Adds 6.5% in Session
  • Zacks · 1d ago
  • JP Morgan Maintains Neutral on Nevro, Lowers Price Target to $90
  • Benzinga · 2d ago

Industry

Medical Equipment, Supplies & Distribution
-0.92%
Healthcare Equipment & Supplies
-1.17%

Hot Stocks

Symbol
Price
%Change

About NVRO

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.
More

Webull offers kinds of Nevro Corp stock information, including NYSE:NVRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVRO stock news, and many more online research tools to help you make informed decisions.